What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that signals the pituitary to release growth hormone. Where natural GHRH has a half-life of a few minutes, CJC-1295 is engineered for durability. Two versions are in common use, and they behave quite differently.

CJC-1295 with DAC (Drug Affinity Complex) includes a chemical modification that binds the peptide covalently to albumin in the bloodstream, dramatically extending its half-life to roughly six to eight days. This version produces a sustained elevation in baseline GH levels rather than distinct pulses — which some researchers argue is less physiologically appropriate, since natural GH secretion is pulsatile, not continuous.

CJC-1295 without DAC (also called Modified GRF 1-29, or Mod GRF) lacks that albumin-binding modification and has a half-life of 30 minutes or less. It acts more like natural GHRH — producing a GH pulse that rises and falls over a couple of hours. This version is nearly universal in stacks with Ipamorelin, where the goal is to produce a physiologically patterned pulse by hitting both the GHRH receptor (CJC-1295) and the ghrelin receptor (Ipamorelin) simultaneously.

When people refer to "CJC-1295" in community contexts without specifying, they almost always mean the no-DAC version.

What Does the Research Say?

Evidence level: Moderate — CJC-1295 has published human pharmacodynamic trials demonstrating dose-dependent GH and IGF-1 increases. This is stronger evidence than most peptides in this space. Therapeutic outcome trials for body composition, recovery, or anti-aging have not been conducted.

Animal Studies

Animal pharmacology for CJC-1295 is consistent with its mechanism. Rodent studies demonstrate that GHRH analogs with extended half-lives produce sustained GH and IGF-1 elevation, with predictable downstream effects on lean mass and bone density. Notably, the with-DAC and without-DAC versions produce different GH secretion profiles in animal models, supporting the mechanistic argument that they are not equivalent.

Human Studies

CJC-1295 has better human data than most peptides in this category, which is worth stating clearly. Teichman et al. published a randomized, double-blind, placebo-controlled study in the Journal of Clinical Endocrinology and Metabolism (2006) examining CJC-1295 with DAC in 65 healthy adults. The study showed dose-dependent increases in mean GH and IGF-1 lasting up to 14 days after a single injection, with no serious adverse events. This is real Phase I/II human data — not outcome data, but it confirms the mechanism works in humans at the doses being studied.

A second study from the same period (Ionescu and Frohman, Journal of Clinical Endocrinology and Metabolism, 2006) provided supporting pharmacokinetic data confirming the albumin-binding mechanism and the extended half-life profile.

These studies used the DAC version. Published human data for the no-DAC version (Mod GRF 1-29) — the version most community users take — is minimal. The pharmacological reasoning for its action is solid, but the specific human PK/PD work is largely absent.

Both studies measured GH and IGF-1 levels, not clinical outcomes. There are no published human trials examining whether CJC-1295 affects body composition, injury recovery, athletic performance, or any of the other outcomes it is most commonly used for.

Community and Anecdotal Reports

CJC-1295 is almost never taken alone. The CJC-1295 no-DAC plus Ipamorelin stack is arguably the most common peptide combination in biohacking and wellness communities. Users report improved sleep quality and more vivid dreams as early effects, followed by changes in recovery, body composition, and skin quality over weeks to months.

These reports align with what elevated GH and IGF-1 would be expected to produce. They are not clinical evidence and are subject to all the standard confounding factors: diet changes, training, placebo effects, variable product quality from research chemical vendors.

Common Uses

Growth Hormone Optimization

This is the primary use. CJC-1295 is used to amplify pulsatile GH secretion, usually in combination with a GHRP like Ipamorelin to hit both arms of the GH-stimulating axis simultaneously. The mechanism is real. Whether the increases at wellness doses translate to meaningful outcomes in healthy adults is not established.

Body Composition

Elevated GH and IGF-1 drive fat mobilization and lean mass synthesis. Community users report changes in body composition over cycles lasting weeks to months, particularly reduced visceral fat. Whether these changes exceed what training and diet achieve independently is not established in controlled trials.

Sleep Quality

Natural GH secretion is highest during slow-wave sleep. Users taking CJC-1295 with Ipamorelin before sleep commonly report deeper sleep and more vivid dreams, which they attribute to amplified GH pulses during that window. The mechanism is plausible. Sleep studies have not been conducted.

Anti-Aging and Recovery

Some physicians prescribe CJC-1295 in compounding contexts for age-related GH decline, which begins in the third decade and continues throughout life. The physiological case for supporting GH axis function is reasonable. The clinical evidence for meaningful outcomes is not there.

For a comparison of how Ipamorelin and CJC-1295 work together, see Ipamorelin: What the Research Says.

Delivery Methods

Subcutaneous Injection

Subcutaneous injection is the only validated route for either CJC-1295 version. The peptide is reconstituted from lyophilized powder in bacteriostatic water and injected into subcutaneous fat.

The practical difference between the two versions matters for dosing frequency. CJC-1295 with DAC produces GH elevation for days to weeks after a single injection, so it is typically dosed once or twice weekly. The no-DAC version produces a pulse lasting a few hours and is typically dosed daily or multiple times per day alongside Ipamorelin.

Timing considerations for the no-DAC version are the same as for any GH secretagogue: fasted state, before sleep or in the morning, to avoid insulin suppression of the GH response.

Oral and intranasal CJC-1295 are not viable. The peptide would be degraded before reaching systemic circulation via oral routes, and no intranasal formulation has been studied.

PEPVi does not provide dosing guidance. Dosing decisions should be made in consultation with a qualified healthcare provider.

Safety and Side Effects

Side effects reported in the Teichman et al. human study were mild: headache, flushing, and injection site reactions were the most common. These are consistent with community reports. Water retention and peripheral edema from elevated GH are reported, particularly at higher doses or with continuous GH elevation from the DAC version. Joint pain and tingling in the extremities (a classic early sign of elevated GH) are reported at doses where GH rises substantially.

The same theoretical concerns that apply to Ipamorelin apply here. Chronically elevated IGF-1 is a recognized cancer risk factor. The risk at the GH elevations produced by typical CJC-1295 doses compared to pharmacological GH therapy doses is unknown. People with a history of cancer should discuss this before use.

The long-acting DAC version carries an additional concern: it produces sustained GH elevation rather than pulsatile release, which some researchers argue is a less physiologically appropriate pattern. The long-term implications of continuous rather than pulsatile GH exposure at these dose levels have not been studied in humans.

CJC-1295 is not FDA-approved for any indication. In October 2023, the FDA proposed restricting CJC-1295 from compounding under 503A and 503B frameworks, the same action that affected Ipamorelin and other peptides. Compounding pharmacies are the main regulated access point, and that pathway has been substantially narrowed.

CJC-1295 is one of the 12 peptides targeted in the current reclassification process. For what changes in July 2026, see What RFK's Peptide Reclassification Means for You.

CJC-1295 is not a scheduled controlled substance. International legal status varies by jurisdiction.

Frequently Asked Questions

CJC-1295 with DAC includes a modification that binds it to albumin in the bloodstream, extending its half-life to roughly six to eight days. It produces sustained GH elevation rather than distinct pulses. The no-DAC version (Mod GRF 1-29) has a short half-life of 30 minutes or less, producing a pulse that mirrors natural GHRH's action. Most community users prefer the no-DAC version, particularly when stacking with Ipamorelin to produce a synchronized, physiologically patterned GH pulse.

They act on different receptors. CJC-1295 acts on the GHRH receptor; Ipamorelin acts on the GHS-R1a (ghrelin) receptor. Together, they stimulate both pathways simultaneously, producing a larger and more sustained GH pulse than either alone. The combination is the dominant protocol in wellness and biohacking contexts.

More than most peptides in this category, yes. The Teichman et al. study (JCEM, 2006) was a randomized, double-blind, placebo-controlled trial in 65 adults showing dose-dependent GH and IGF-1 increases. That is real Phase I/II human data confirming the mechanism. What doesn't exist is outcome data: no trials have measured whether CJC-1295 affects body composition, recovery, or any other endpoint people use it for.

Short-term side effects are mild based on clinical data and community reports. The unresolved question is long-term safety, particularly around sustained IGF-1 elevation and its cancer risk implications. The with-DAC version's continuous GH profile adds an additional unknown. Long-term safety data in humans at wellness doses does not exist.

Learn More

Sources

  1. Teichman SL, Neale A, Lawrence B, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism, 2006. — Randomized, double-blind, placebo-controlled trial in 65 adults; the primary human evidence for CJC-1295's mechanism and safety profile.

  2. Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." Journal of Clinical Endocrinology and Metabolism, 2006. — Pharmacokinetic characterization of the albumin-binding mechanism and sustained GH secretion profile.

  3. FDA. "Bulk Drug Substances Used in Compounding Under Section 503A." October 2023. — Regulatory action restricting CJC-1295 from 503A compounding; the basis for current US access restrictions.